- Nearly 5000 pregnant women are infected with COVID-19
- Powell dies due to COVID-19 Also suffered Multiple Myeloma
- Hundreds millions of Nike shoes could not be delivered due to COVID-19
- How long is the protection period of COVID-19 vaccines?
- What are the differences between the current COVID-19 vaccines?
- Will EMT become the new target for the treatment of colorectal cancer?
Italy report: Pfizer COVID-19 vaccines may be less effective for fat people
Italy report: Pfizer COVID-19 vaccines may be less effective for fat people. After Norway announced that the Pfizer vaccine was too risky for the elderly and terminally ill patients, Italy also raised its own doubts. According to the “Guardian” report on February 28, Italian researchers found in experiments that the Pfizer vaccine is less effective for obese people. Compared with healthy vaccinators, obese people have a 50% reduction in antibody levels after the second dose of vaccine.
Screenshot of “Guardian” report On February 26, Aldo Venuti, a medical doctor of the Italian Ministry of Health, issued a report saying that he and his colleagues vaccinated 248 medical staff with two doses of Pfizer vaccine and continued to observe the vaccination. The person produces an antibody response. Seven days after the second dose of vaccine was injected, 99.5% of the test subjects had an antibody reaction, and the reaction intensity was higher than that of patients who recovered from the new coronavirus pneumonia. However, obese people have a weaker response to the vaccine.
Experimental results showed that after receiving the second dose of Pfizer vaccine, the antibody level of obese people was only 50% of that of healthy vaccinators. Although it is not yet known what this means for the effectiveness of the vaccine, it may mean that obese people must be adequately protected and may need to be vaccinated with additional vaccine agents.
“Obesity is a major risk factor for the morbidity and death of patients with COVID-19,” the report said, “it is therefore necessary to develop an effective vaccination plan in this subgroup.”
The report also said that this data is of great significance to the COVID-19 vaccine vaccination strategy, especially for obese people. After the data has been studied on a larger scale, it may be helpful to formulate an additional dose of vaccine for obese people.
Danny Altmann, professor of immunology at Imperial College London, said that people have always known that the BMI of the vaccinator is closely related to the effect of the vaccine. This report proves that vaccination does not mean immunity to the virus, especially “in a country with a high obesity rate.” In addition, this report also emphasizes that after vaccination, a long-term immunization monitoring plan is still needed.
In another study of Brazilian medical staff, Altman and his colleagues also found that in people with higher BMI, secondary infections of the new coronavirus are also more common. In addition, after they were infected with the virus for the first time, their antibody response was relatively weak.
In fact, as early as August 26 last year, the Guardian reported a study by the University of North Carolina at Chapel Hill that the COVID-19 vaccine may be less effective for obese people. In addition, for obese people with a body mass index (BMI) of more than 30, the new coronavirus means a greater threat. Research reports show that the risk of obese people being hospitalized with the epidemic has increased by 113% compared with ordinary people, and the risk of death from the virus has increased by nearly 50%. Part of the reason is that obese people often have other underlying diseases, and it may also be metabolic problems such as insulin resistance caused by excess fat in their bodies.
The World Health Organization (WHO) defines “overweight” as a BMI over 25, and “obesity” as a BMI over 30. According to the Guardian, the United States and the United Kingdom are the two countries with the highest obesity rates in the world: US government data shows that more than 40% of Americans are obese, while more than 27% of British adults are obese.
In addition to obese people, the elderly and terminally ill patients also need to “raise vigilance” on Pfizer vaccines.
On January 18, local time, the official website of the Norwegian Drug Administration (NOMA) reported that as of the 14th, there were 23 suspected deaths after vaccination.
The FDA stated in the announcement that Norway is currently vaccinating elderly people with serious underlying diseases and people in nursing homes. Therefore, deaths close to the time of vaccination are expected.
However, Norway still proposes that the COVID-19 vaccine may be too risky for the elderly and terminally ill patients. This is the most cautious statement ever issued by the European health authorities.
Since European countries started vaccination, Pfizer vaccine has been frequently questioned.
At the end of January, a COVID-19 pneumonia epidemic occurred in a nursing home in Spain. All 78 elderly people in the hospital were diagnosed and 7 died. The staff of the nursing home revealed that a few days before the outbreak of the epidemic in the hospital, all the elderly had just finished the first dose of Pfizer’s vaccine.
On February 7, 14 elderly people in a nursing home in Germany were still diagnosed with the variant virus after being vaccinated with two doses of Pfizer vaccine.
In addition, Pfizer announced on February 18 that it would launch the first clinical trials for pregnant women in the United States. However, the WHO issued a document on January 8 stating that certain groups of people are not recommended to be vaccinated, including “most pregnant women.”
(source:internet, reference only)